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Abstract
Renal physiology and physiopathology have been the object of studies aimed at 
developing exams that can assist in the early diagnosis of the base disease. Chronic 
kidney disease consists of the progressive, irreversible loss of kidney function. Early 
detection and appropriate treatment can minimize the progression of the disease, 
lower the inherent costs, and improve the quality of life of affected individuals. 
Kidney biopsy is the key method in this evaluation, as it enables the histological 
and immunohistochemical analysis of specimens in a fast, safe, and economical 
manner. The main indications for kidney biopsy are nephrotic syndrome, acute 
kidney failure of unknown etiology, persistent hematuria and proteinuria, chronic 
kidney disease with conserved kidney dimensions, and transplanted kidneys (to 
evaluate stages of rejection, infection, and/or sclerosis). However, as an invasive 
method, kidney biopsy is not without complications. Post-biopsy complication rates 
range from 5 to 15%, with 6.6% considered minor (macrohematuria with no need 
for blood transfusion) and another 7.7% considered major (hemorrhage requiring 
blood transfusion or other approaches). In this chapter, we address the main aspects 
of kidney biopsy, the technical procedures for its execution, and the management of 
the main complications stemming from this procedure.
Keywords: kidney biopsy, percutaneous kidney biopsy, post-biopsy complications, 
complications, ultrasound-guided biopsy
1. Introduction
Renal lesions are subdivided based on duration as acute kidney injury (AKI) and 
chronic kidney disease (CKD). AKI has numerous hemodynamic, inflammatory, 
toxic, and obstructive causes, which, when diagnosed and treated early, can be 
reversed, thereby avoiding permanent damage [1, 2]. CKD, however, is the clinical 
detection of a progressive, irreversible loss of kidney function, for which the aim of 
therapy is to minimize the progression of the disease [2].
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Percutaneous kidney biopsy has become part of clinical practice in nephrology, 
as it enables the diagnosis, prognostic assessment, and therapeutic guidance of 
kidney diseases [3, 4]. Since its advent in the 1950s, advances have been achieved in 
the technique to improve the diagnostic yield and minimize complications [5].
2. Percutaneous ultrasound-guided renal biopsy
2.1 Indications
The indication for a kidney biopsy is determined mainly by signs and symptoms 
[4]. The global rate of biopsy (number of procedures per million [ppm]) in native 
kidneys ranges from more than 250 ppm in Australia to less than 75 ppm in the 
United States. This divergence in kidney biopsy rates is influenced by the prevalence 
of kidney disease as well as different opinions regarding the value of the procedure 
in terms of diagnosis, prognosis, and therapy [6].
The main objectives that lead to the indication for kidney biopsy are the need for 
a precise diagnosis and treatment, the need to determine the degree of activity and 
chronicity of the lesion in order to establish the prognosis and possible response to 
treatment, and the evaluation of genetic diseases [6]. The diagnostic contribution 
of a kidney biopsy is undeniable in cases of nephrotic syndrome, systemic disease 
kidney failure, unexplained AKI, and transplanted kidney dysfunction [7].
For cases of idiopathic nephrotic syndrome in adults and children older than 
6 years of age, the indication for a kidney biopsy is extremely important, as the 
findings often influence therapeutic decision-making [8]. In a prospective study 
involving 276 biopsies of native kidneys, the diagnosis resulting from the biopsy 
influenced the management of 86% of cases of nephrotic syndrome [9]. However, 
there is a variety of clinical situations of nephrotic syndrome for which a kidney 
biopsy is not generally performed at the time of diagnosis, such as in cases of 
children between 1 and 6 years of age due to the high prevalence of minimal change 
disease [10, 11]. In such situations, corticotherapy is indicated and biopsy is only 
performed in cases of therapeutic failure or the appearance of another sign or 
symptom not associated with minimal change disease [11]. Biopsy is also not per-
formed initially in cases of secondary nephrotic disease clearly associated with the 
introduction of a medication known to cause this condition, such as non-steroidal 
anti-inflammatory drugs, gold salts, pamidronate, penicillamine, and lithium. 
This group includes patients with longstanding diabetes with gradual proteinuria 
progression, those with morbid obesity and slowly increasing proteinuria accom-
panied or not by diabetes and worsening kidney function, those with systemic 
diseases such as primary or secondary amyloidosis in which the diagnosis can be 
made through less invasive methods, such as adipose tissue biopsy, and patients 
known to have malignant diseases involving nephrotic syndrome [6]. Patients with 
nephrotic syndrome generally exhibit hematuria, proteinuria, hypertension, and 
renal dysfunction, and the condition is also often associated with systemic diseases. 
Therefore, kidney biopsy contributes to the diagnosis, therapeutic decision-making, 
and classification of the disease (e.g., systemic lupus erythematosus). In suspected 
cases of post-streptococcal glomerulonephritis, biopsy is only recommended when 
a gradual worsening in serum levels of creatinine, prolonged hypocomplement-
emia, and recurring hematuria are observed [6, 7].
Cases of systemic diseases with kidney failure include non-nephrotic protein-
uria, isolated glomerular hematuria, and unexplained CKD. Protein is a marker 
and factor related to the progression of kidney disease. Studies have demonstrated 
a relation between the degree of proteinuria and the progression of CKD in cases 
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of non-nephrotic proteinuria [7]. Thus, many nephrologists routinely perform a 
kidney biopsy in patients with higher non-nephrotic proteinuria (1–2 g/day) in 
the absence of another clinical condition that might explain the findings (e.g., 
diabetes mellitus or hypertension). However, in situations of low-grade proteinuria 
(500–1000 mg/day) in the absence of glomerular hematuria, altered kidney func-
tion, and clinical/serological evidence of a systemic disease, a biopsy is generally not 
performed [6]. Biopsy in cases of isolated glomerular hematuria remains contro-
versial, as the procedure exerts little influence on therapeutic decision-making. 
When performed, the conditions most often encountered are Alport syndrome, 
thin basement membrane nephropathy, and immunoglobulin A nephropathy. In a 
prospective analysis, biopsy influenced the therapeutic decision-making in only one 
of the 36 procedures performed [9]. For patients with unexplained CKD, a kidney 
biopsy can provide important information, despite the greater risk of complica-
tion. In cases of exacerbated CKD, a biopsy may reveal lesions that can be treated 
and reversed. Moreover, a biopsy can contribute important knowledge to clinical 
management in cases of the need for a kidney transplant [7].
For patients with unexplained AKI, biopsy is indicated in cases of an uncertain 
etiology and can influence clinical management in 71% of cases [9]. Biopsy is also 
particularly useful for early or late-onset dysfunction of a renal graft. In cases of 
acute graft dysfunction, the procedure enables confirming the diagnosis of rejec-
tion and specifying the pathological mechanism (acute cellular rejection or anti-
body mediated rejection). Late biopsies also furnish essential information to assist 
in differentiating the causes of chronic nephropathy of the graft, such as chronic 
rejection, transplant glomerulopathy, nephrotoxicity, viral disease, lymphopro-
liferative diseases, and relapse of the base disease. The simplicity of the technical 
procedure and richness of the diagnostic and prognostic information make biopsy 
indispensable to the follow-up of renal grafts [7].
Contraindications for kidney biopsy may be absolute or relative. For percu-
taneous kidney biopsies, absolute contraindications include uncontrolled severe 
hypertension, the inability of the patient to cooperate with the biopsy, having only 
one kidney, and uncontrollable hemorrhagic diathesis, whereas relative contraindi-
cations include severe azotemia, anatomic kidney abnormalities, anticoagulation, 
pregnancy, and urinary tract infection [3].
2.2 Techniques and materials
Kidney biopsies can be guided by different imaging methods, the most common 
of which are ultrasound (US) and computed tomography (CT) due to their good 
performance and broad availability. In contrast, magnetic resonance is employed 
little due to the greater cost and need for specific material. The choice between US 
and CT should be individualized and based on the physician’s experience, kidney 
volume, location of the biopsy site, patient’s clinical condition, and the availability 
of the equipment. US is generally the imaging method of choice for guiding a 
kidney biopsy, since it enables obtaining samples from virtually any site and visual-
izing the needle in real time. It also does not expose the patient to radiation, can be 
performed in any environment, including at the bedside, and enables the continual 
monitoring of any pre-operative complications. It is also the method of choice for 
post-procedure follow-up, enabling the early detection of complications [4].
To be successful, US-guided kidney biopsy requires specific conditions. The 
patient must be placed in ventral decubitus on the examining table and the proce-
dure must be performed in a sterile environment. The transducer should be covered 
with a sterile film. There are specific transducer covers on the market, but a sterile 
glove can be used in cases of emergency. Antisepsis should be performed on the 
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entire side of the back corresponding to the kidney to be biopsied. The selection 
of the puncture site is determined by US considering the best path (least distance 
between the skin and renal capsule and the absence of vascular structures and/or 
interposed intestinal loops). This region in the center of the US image ensures the 
safest path for the biopsy and provides better control and resolution of the image.
Once the region to be punctured has been defined, the skin at the puncture site is 
anesthetized and the area of anesthesia is then extended to the deep layers, prefer-
ably reaching the perirenal layers, including adjacencies external to Gerota’s fascia 
and the renal capsule. An alternative is the use of a long 18G peripheral intravenous 
catheter with the administration of 20 ml of anesthetic solution (10 ml of 2% xylo-
caine with no vasoconstrictor +10 ml of 0.9% saline solution or bi-distilled water). 
The entire anesthetic procedure as well as the subsequent steps should be guided 
by US. Some authors prefer performing a biopsy with their hands free. The two 
techniques (with or without US) have the same rates of minor and major complica-
tions and obtain adequate material for analysis, but the hands-free method requires 
greater experience and has a somewhat slower learning curve [1, 12]. Next, the 
biopsy needle is aligned with the transducer (when US is used) and introduced at a 
45° angle to the skin. To ensure the safety of the procedure and control of complica-
tions, both the needle and its path should be kept within the US viewing field. The 
path to follow with the needle in the renal parenchyma should only involve the renal 
cortex (glomerular region), without transfixing the renal medulla, which contrib-
utes little to the study and has large-caliber vessels that could be associated with 
vascular complications; this also avoids the occurrence of injury to the renal calyces 
and pelvis [4, 13]. The number of fragments to collect depends on the number 
and types of exams requested as well as the presence of the pathologist during the 
exam, who may express opinions regarding the quality of the specimen collected. 
In procedures without the presence of a pathologist, two fragments are normally 
collected for each exam solicited.
Different needle calibers, lengths, and tip shapes are available on the market 
for the collection of material for microscopic analysis. Thin-needle punctures are 
performed with calibers ranging from 20 to 25, whereas thick-needle biopsies are 
performed with 14- to 19-gauge needles. Authors state that thin needles provide 
smaller fragments for analysis, but the fragments have similar quality and anatomo-
pathological interpretation to those obtained with thick needles. Nonetheless, larger 
fragments enable a more complete study of renal pathologies. Moreover, although 
a smaller caliber is related to a lower rate of complications stemming from the 
procedure, it does not assist in the renal evaluation [14]. Along with a core biopsy 
needle (thick needle), coaxial needles can be used, which have a larger diameter 
with sufficient inner diameter to enable the navigation of the core biopsy needle in 
its interior. The use of coaxial needle kits avoids multiple punctures of the capsule, 
as this mechanism enables acquiring several tissue samples with a single perfora-
tion, which reduces the procedure time. However, portions of the organ cannot be 
sampled with this method and the use of such needles increases the cost of the pro-
cedure. The use of coaxial needles enables the operator to easily embolize the needle 
path with an absorbable gelatin sponge when removing the outer needle at the end 
of the procedure. This embolization promoted by the coaxial method is believed to 
reduce the risks of post-biopsy bleeding, but this characteristic is reported to not 
be an advantage of the method. Thus, both the coaxial and non-coaxial techniques 
do not appear to influence the bleeding complication rate [15]. The use of spring-
loaded tools is currently recommended. These needles are classified based on the 
form of discharge into the tissue: automatic or semi-automatic (disposable). Such 
tools are reported to be more effective and safer than classic percutaneous renal 
biopsies that use the Tru-Cut or Vim-Silverman needle. Automatic tools are more 
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economical, since only part of the kit is disposable. However, the disadvantage is the 
lower control over the progression of the needle during discharge and capture of the 
fragment as well as the longer procedure time due to the increase in the number of 
preparation steps of the needle/spring-loaded tool with the risk of contamination. 
Semi-automatic tools are more costly due to the fact that the entire system is dispos-
able. The advantages are the security in maintaining all material sterile throughout 
all steps of the procedure, greater control over the advancing of the needle for the 
extraction of the fragment, the possibility of checking the intralesional position 
prior to discharge, and the reduction in procedure time, since no preparation of the 
needle and spring-loaded tool is needed.
Prior to presenting the biopsy technique to the patient or legal guardian, it is 
advisable to consult with the physician in charge of the procedure. This moment 
orientates the patient and family regarding the risks, benefits, and preparation 
for the procedure. It is also possible to identify possible techniques linked to the 
peculiarities of each patient, such as having a physical disability that precludes the 
standard position, deforming kyphoscoliosis, scars, skin diseases, and anxiety dis-
orders. To ensure a successful examination, it is of extreme importance to evaluate 
recent laboratory exams (within the previous 30 days) and determine the patient’s 
health condition. Patients should meet basic criteria before being submitted to the 
procedure (Table 1). If a patient does not meet the minimum requirements, the 
procedure should be rescheduled until after the base disorder has been corrected. 
For patients with an urgent need for the procedure, immediate corrective measures 
should be assessed. For instance, plasma and platelet transfusion may be options in 
cases of a high international normalized ratio (INR) and low platelet count, respec-
tively. An imaging study should be performed prior to the kidney biopsy to gain 
knowledge on renal anatomy and determine the presence of ectopias, congenital 
dysplasia, or polycystic kidneys.
2.3 Quality of material/pathologist present
A kidney biopsy is an important diagnostic tool and considered the “gold 
standard” for the best definition of the majority of nephropathies. It is capable of 
changing the clinical diagnosis approximately 50% of the time and changing the 
therapy to be administered approximately 40% of the time [16]. For this to happen, 
however, an adequate sample must be obtained.
A 19-gauge needle generally furnishes very small, narrow specimens that are 
often inadequate for the assessment of vessels. Thus, smaller needles, such as 18 or 
Criteria that impede a kidney biopsy
Clotting disorders characterized by prothrombin activity <60%
INR > 1.3
Platelet count <60,000/mm3
Use of anticoagulant
Systolic BP > 140 mm Hg
Urinary infection
Acute persistent cough
Skin lesions at puncture site
Altered mental state
Table 1. 
Conditions that impede a kidney biopsy.
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16 gauge, are advisable [17, 18]. Depending on the needle used, the difference in the 
obtainment of glomeruli can be as high as 300% [19]. The quantity of glomeruli 
needed for a secure diagnosis depends mainly on the diagnostic hypothesis and 
the clinical condition of the patient. For virtual exclusion (with greater than 95% 
certainty) of the diagnosis of focal segmental glomerulosclerosis, it is essential to 
have at least 25 glomeruli representing the juxtamedullary portion, as the focal 
disease affects some glomeruli while sparing others of morphological abnormalities 
seen with light microscopy and a good sample is important to the best definition of 
the disease [20]. In contrast, the diagnosis can be confirmed with a single glom-
erulus for other diseases, such as membranous glomerulopathy, in which diffuse 
morphological changes are similar in all glomeruli. For still other diseases, such as 
myeloma nephropathy, the diagnosis is essentially confirmed with representation 
of the medullary portion. In the analysis of transplanted kidney tissue, the aim is to 
achieve at least two core fragments exhibiting at least 7–10 glomeruli, two arteries, 
and the medullary portion (minimum assessment criteria defined by the Banff 
Meeting) [21].
In the evaluation of most glomerulopathies by light microscopy or immuno-
fluorescence microscopy, 8–10 glomeruli are needed [22]. During the US-guided 
removal of the fragment, the evaluation of a pathologist is very important, as he/
she is capable of determining the adequacy of the sample. The examination of the 
fresh material determines its sufficiency (quantity of glomeruli) for testing the 
main clinical hypotheses and provides information on medullary representation as 
well as the representation of larger vessels (Figure 1).
After determining the ideal amount of material and its representation of the 
renal parenchyma, the pathologist stores the samples in specific solutions for dif-
ferent analyses. The solutions should not come into contact with each other, as this 
would render the subsequent analyses unviable. The largest portion of the fragments 
should be allocated to light microscopy analysis. The most widely used fixatives are 
Figure 1. 
Ultrasound-guided kidney biopsy. Fragment stored in 0.9% NaCl and analyzed under a light microscope. 
Renal medulla with medullary rays and characteristic striation. Multiple small round structures (glomeruli) 
distributed in renal cortex—some paler, others congested with numerous red blood cells (details of two 
glomerular structures).
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10% neutral buffered formalin, paraformaldehyde, and Bouin’s solution. In these 
media, the sample remains viable for analysis for several days. However, earlier 
histological processing results in analyses of better quality. For the analysis of 
antigens, such as IgG, IgM, IgA, complement components C3 and Cq1, fibrinogen as 
well as κ and λ chains, immunofluorescence microscopy should be used. Therefore, 
the sample should be stored in 0.9% saline solution—if the collection site is near the 
analysis site—and kept chilled (but not frozen) to obtain the best possible results. If 
rapid analysis (within several hours) is not possible, the sample should be placed in 
a transport solution, such as Michel’s or Zeus solution. Although this solution pre-
serves the sample for several days, better results are achieved the earlier the sample 
is taken for analysis, with poor or even impossible results if the sample is analyzed 
5–7 days after being collected [23]. For transmission electron microscopy, a small 
portion is needed of the cortical parenchyma, with two glomeruli. This analysis is 
essential to the evaluation of podocytopathies, thin basement membrane disease, 
and metabolic disease. The fragments should be fixed within minutes after collec-
tion in a specific solution (glutaraldehyde or Karnovsky’s solution). In the presence 
of a pathologist, a small portion may be acquired (1 and 2 mm) and fragmented 
until obtaining the quantity of glomeruli needed. This material should be placed in a 
buffered solution after fixation (1–2 days after collection), as the aim of the analysis 
is to examine the ultrastructure, such as the cytoplasmic membrane, reticulum, and 
immune deposits, which are lost if not fixed soon enough.
When a biopsy is performed without the presence of a nephropathologist, it is 
advisable to remove at least one fragment (if possible, two) from the renal paren-
chyma for each solution. Immunohistochemical analysis for the study of C4d, poly-
omavirus, adenovirus, cytomegalovirus, PLA2R, IgG4, etc. should be performed 
with material embedded in paraffin, which is preserved for light microscopy.
2.4 Complications and management
A kidney biopsy is considered a minimally invasive method but is not without 
complications. Depending on the severity, such events are classified as minor and 
major, which require different forms of treatment (Table 2). Minor complications 
include hematuria, small perirenal hematomas, arteriovenous fistulas, and pain, all 
of which normally resolve spontaneously [24]. Major complications include massive 
bleeding with hemodynamic instability, voluminous perirenal hematomas with 
refractory disabling pain, and important hematuria with obstruction of the urinary 
tract by clots. In such cases, management is normally necessary.
Among all forms of complication, bleeding is the most frequent and occurs 
mainly within the first 12–24 hours after the procedure in nearly all patients [4, 25]. 
Complications Management
Major complications
Disabling intense pain Optimization of analgesia (use of opioids)
Hemodynamic instability with blood transfusion Endovascular treatment (embolization)
Clot obstructing urinary tract Irrigation with three-way probe
Minor complications
Arteriovenous fistula Conservative
Hematuria Hydration
Table 2. 
Post-biopsy complication and proper management for each.
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Microscopic hematuria, mild low back pain, and a slight drop in the hemoglobin 
concentration are frequent findings and should not be considered complications 
[25]. However, the persistence of these symptoms for more than a week may require 
a detailed investigation with imaging exams. Post-biopsy chronic hypertension, the 
puncture of other organs, and perirenal soft part infections have been described but 
are very rare.
The literature reports variable complication rates, generally ranging from 5 to 
16%, with macroscopic hematuria in 3–9% of cases and the need for transfusions in 
0.1–3.0% of cases [14, 26–29]. In such cases, an exploratory ultrasound examination 
should be performed (Figure 2). Burstein et al. found post-biopsy complications in 
14.3% of patients, with 6.6% considered minor and another 7.7% considered major 
(hemorrhages requiring blood transfusion or another approach) [28]. González-
Michaca et al. found major complications in 2.4% of patients and minor complica-
tions in 8.65%, the most frequent of which was perirenal hematoma [30, 31]. Native 
kidneys tend to have a lower complication rate than transplanted kidneys (13.9 and 
24.4%, respectively) [32].
Figure 2. 
Exploratory ultrasound performed on patient with gross hematuria, 24 hours after percutaneous native kidney 
biopsy. (A and B) Multiple pelvic blood clots (arrow) after renal biopsy.
Figure 3. 
Perirenal hematoma, an hour after percutaneous native kidney biopsy. Computed tomography (CT) scan slices 
of the abdomen revealed voluminous perirenal hematoma (yellow circle), on the left side. (A and B) Axial 
scan slices. (C) Coronal scan slice. (D) Coronal scan slice.
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After a kidney biopsy, patients should remain in observation for at least 4 hours. 
They are placed at absolute rest in dorsal decubitus and are monitored in this period 
with the constant evaluation of vital signs. It is also advisable to perform renal 
ultrasound 1 hour after the procedure in all patients submitted to percutaneous 
kidney biopsy. The aim of this measure is to evaluate the biopsied area and antici-
pate possible post-procedure complications, thereby enabling immediate, effective 
therapeutic support (Figure 3 and Figure 4).
The volume of the perirenal hematoma formed and the complication rates 
associated with this procedure have a direct relation of proportionality. Hematomas 
formed in the first hour after the procedure with volumes greater than 40 ml are 
related to a greater risk of developing major complications [14] (Figure 5). For cases 
of minor complications, the patient should receive clear orientation regarding the 
expected benign evolution of the case and receive medication for the symptoms 
based on individual need. These patients should be required to return after 7 days 
for a follow-up ultrasound and definitive discharge of the case if no imaging 
abnormalities are found and there are no new complaints. In cases of hemodynamic 
Figure 4. 
Post-biopsy procedures and management.
Figure 5. 
Perirenal hematoma, observed an hour after percutaneous native kidney biopsy. (A) Longitudinal 
ultrasonography exhibiting hematoma area near the posteroinferior border of the left kidney. (B and C) 
Longitudinal (line 1) and transversal dimension on ultrasound (line 2 and 3) estimated the final volume of 
216.73 ml of hematoma area. LK, left kidney; H, hematoma.
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instability, the patient should receive adequate clinical measures at an intensive 
care unit, followed by an angiographic study. Digital angiography remains the gold 
standard for the anatomic study of the renal arteries, but computed tomography 
angiography (angiotomography) has gained popularity, offering comparable accu-
racy and the advantage of evaluating not only the lumen, but its walls and other 
visceral changes [32].
Figure 6. 
Renal arteriography, 2 hours after percutaneous native kidney biopsy. (A) Pre-embolization arteriography 
revealed pseudoaneurysm in a lower renal pole (yellow arrow). (B) Post-embolization superselective 
arteriography revealed absence of pseudoaneurysm with preservation of the local vasculature (yellow arrow).
Figure 7. 
Endovascular embolization. (A) A catheter is inserted into femoral artery, by the groin area to access vessels 
of the kidney and into vascular rupture site. (B) Rupture in arterial blood vessel, which will receive a catheter 
and embolization material to achieve occlusion.
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After renal vascular mapping and if signs of active bleeding are identified 
(active escape of contrast medium, pseudoaneurysms, or arteriovenous fistulas), 
endovascular treatment is indicated, which is a minimally invasive procedure that 
should be performed by an interventionist radiologist or professional who is duly 
trained and certified in endovascular techniques (Figure 6). The procedure can be 
performed through femoral or radial artery access, always initiated with an ana-
tomic study of the renal arteries and respective variations. When a probable focal 
hemorrhage is identified, superselective arteriography is performed in a coaxial sys-
tem with a microcatheter and microguide, followed by superselective embolization 
techniques performed on the compromised vessel. For interventional treatment, the 
selection of appropriate embolic agents for superselective embolization is the key 
to achieving desirable outcomes (Figure 7). Embolic agents include PVA particles, 
coils, and gelatin sponge strips, which can be used either alone or in combination 
[33]. The de-vascularized area will suffer infarction, which could cause a momen-
tary change in renal function. Thus, more selective catheterism leads to a lower risk 
of this complication. Pseudoaneurysms are pulsating masses at puncture sites due 
to the rupture of the arterial wall and extravasation of blood, generally associated 
with local pain and hematoma. Hemodynamic instability and a drop in hemoglobin 
concentration may be related to the rupture of pseudoaneurysms. The treatment 
for pseudoaneurysms and arteriovenous fistulas is recommended for persistent 
bleeding for more than 72 hours or in cases of the accentuated loss of kidney 
function after the procedure. It should be stressed that most pseudoaneurysms less 
than 2.0 cm and arteriovenous fistulas progress with thrombosis and spontaneous 
resolution within 4 weeks, making conservative treatment the conduct of choice 
in cases without hemodynamic instability. Patients should remain in intensive care 
for at least 24 hours after the procedure and a follow-up imaging method should be 
performed prior to the decision regarding the discharge of these patients.
3. Conclusion
Imaging-guided renal biopsy is a useful tool for the evaluation and management 
of renal diseases. This chapter summarizes that percutaneous ultrasound-guided 
renal biopsy is a safe technique which allows the evaluation of renal disease but is 
associated with post-biopsy complications. We discuss indications and approach to 
imaging-guided percutaneous renal biopsies as well as complications and manage-
ment associated with this.
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